https://doi.org/10.55788/c3dd6474
Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« AHA 2022 Highlights Podcast Next Article
Belimumab efficacious in cutaneous lupus erythematosus »
« AHA 2022 Highlights Podcast Next Article
Belimumab efficacious in cutaneous lupus erythematosus »
Table of Contents: ACR 2022
Featured articles
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?
Early treatment: a key to improved outcomes in polyarticular JIA
ACR 2022 Congress Round-Up
Glucocorticoids in rheumatic diseases: Is there a skeletal sparing dose?
Bimekizumab: Robust 1-year results in treating psoriatic arthritis
Stimulation of PD-1: a new concept to treat RA
Denosumab in erosive hand arthritis: Structure repair of interphalangeal joints seems possible
High retention rates after switching between infliximab biosimilars
New analysis assesses the safety of tofacitinib regarding extended MACE
Lack of vaccination results in a higher frequency of pre-term births in pregnant women with rheumatic disease and COVID-19
Ankylosing spondylitis: Combining biologics with NSAID does not imply reduced radiographic progression
Diet and exercise programme: a successful OA strategy in a community-based setting
Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?
A novel risk score helps identify interstitial lung disease in patients with systemic sclerosis
Early treatment: a key to improved outcomes in polyarticular JIA
TYK2 inhibition shows potential as a treatment for SLE
Belimumab efficacious in cutaneous lupus erythematosus
No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies
Related Articles
December 9, 2021
Immune-mediated diseases tied to risk of cancer
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy